WinwinGPT is coming soon! Join the waitlist now!

Nektar therapeutics

US StockHealth Care

NKTR AI Analysis Overview

Keys for Bullish View

  • Value≥4
  • Dividend≥2

Analysis Conclusion

The stock has been awarded the top rating for its value, but its dividend score is below 2. If the company starts distributing dividends, it may yield even better investment results.

NKTR Current Performance

22.48%

Nektar therapeutics

0.37%

Avg of Sector

0.74%

S&P500

Top 10 High Relevance to NKTR

  • VTGN Vistagen therapeutics, inc.
    Value 4Trend 4Swing Trading 2Whale Interest 2Dividend 1
    See more

NKTR Profile

Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body's immune response to fight cancer. Its pipeline includes NKTR-255, Rezpegaldesleukin (REZPEG) and NKTR-0165. NKTR-255 is an investigational biologic that is designed to target the interleukin-15 (IL-15) pathway in order to activate the body's innate and adaptive immunity. Its Rezpegaldesleukin pipeline is an investigational, potential first-in-class T regulatory cell stimulator that addresses this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. Rezpegaldesleukin is being developed as a self-administered injection.

Price of NKTR